Sign In
Buy INVA
$23.55
+0.88 (+3.88%)
At Close: Jun 23, 2026
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
09:00am, Thursday, 18'th Jun 2026
Nortiva Bio, Inc. (âNortivaâ) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines u
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
08:00am, Thursday, 18'th Jun 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using i
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreem
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
05:38pm, Monday, 08'th Jun 2026
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva to Participate in Upcoming Investor Conferences
12:01pm, Monday, 01'st Jun 2026
Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica
Innoviva to Participate in Upcoming Investor Conferences
11:00am, Monday, 01'st Jun 2026
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical ca
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
06:35pm, Friday, 29'th May 2026
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
Innoviva (INVA) Tops Q1 Earnings Estimates
10:45pm, Wednesday, 06'th May 2026
Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
04:05pm, Wednesday, 06'th May 2026
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical ca
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
08:41am, Thursday, 30'th Apr 2026
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:10am, Saturday, 18'th Apr 2026
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One equit
3 Bargain-Cheap Small Caps Worth a Second Look
08:24am, Thursday, 09'th Apr 2026
The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.
Innoviva (NASDAQ:INVA) Shares Cross Above 200 Day Moving Average – Here’s What Happened
03:20am, Tuesday, 07'th Apr 2026
Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $20.50 and tra
Analysts Set Innoviva, Inc. (NASDAQ:INVA) Price Target at $34.80
01:31am, Friday, 27'th Mar 2026
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat Ratings report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of
